TABLE 3.
UL54 mutations in clinical CMV isolates resistant to antiviral agents
| Region | UL54 mutationa | Amino acid change | Viral phenotypeb
|
UL97 mutationsc | Reference(s) | ||
|---|---|---|---|---|---|---|---|
| Ganciclovir | Foscarnet | Cidofovir | |||||
| IV | N408D | Asparagine to aspartic acid | R | S | R | No | 30, 58 |
| F412C | Phenylalanine to cysteine | R | S | R | Yes | 14, 58 | |
| D413E | Aspartic acid to glutamic acid | R | S | R | Yes | 30 | |
| ∂-region C | L501F | Leucine to phenylalanine | R | S | R | Yes | 30, 37 |
| L501I | Leucine to isoleucine | R | S | R | Yes | 58 | |
| T503I | Threonine to isoleucine | R | S | R | Yes | 58 | |
| K513R | Lysine to arginine | R | S | R | Yes | 58 | |
| K513E | Lysine to glutamic acid | R | S | R | Yes | 59 | |
| P522A | Proline to alanine | R | S | ND | Yes | 30 | |
| T700A | Threonine to alanine | R | S | R | No | 30 | |
| II | T700A | Threonine to alanine | S | R | S | No | 3 |
| M715V | Valine to methionine | S | R | S | No | 3 | |
| I722V | Isoleucine to valine | R | S | R | Yes | 58 | |
| VI | V781I | Valine to isoleucine | R | R | S | Yes | 58 |
| III | L802M | Leucine to methionine | R | R | S | Yes | 14 |
| A809V | Alanine to valine | R | R | S | Yes | 15 | |
| G841A | Glysine to alanine | R | S | ND | Yes | 30 | |
| Other | S676G | Serine to glysine | R | S | R | Yes | 58 |
| G678S | Glysine to serine | R | S | R | Yes | 59 | |
| Y751H | Tyrosine to histidine | R | S | R | Yes | 58 | |
a
Mutations transferring antiviral resistance to recombinant viruses are shown in boldface type.
b
R, S, and ND denote resistant, sensitive, and not done, respectively.
c
Refers to ganciclovir resistance UL97 mutations.